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Lung cancer is giving promising results in immunotherapy treatments, even though 
it is one of the cancers with worse prognosis. Silencing of the PD1 / PDL-1 pathway is 
one of the most widely used strategies for this type of cancer. This pathway is usually 
found to be overexpressed in lung cancer; it should be noted that it helps tumor cells to 
evade the anti-tumor response of the immune system. PPRHs are DNA molecules used 
for gene silencing. They were recently discovered and have been previously tested in 
other types of cancer to modulate the PD1 / PDL-1 pathway. During the present research 
project, the main objective was to validate the PPRHs strategy to inhibit the PD1/PDL-1 
pathway as a possible treatment of pulmonary adenocarcinoma. THP-1 cells were 
differentiated to macrophages with PMA. Different PPRHs against PD1 and PDL-1 were 
designed and tested in THP-1 and A549 cell lines, first separately, testing for cross 
toxicity and then in co-culture. Cell viability was assessed by MTT assays. Differentiation 
of THP-1 to macrophages showed no significant differences at three different 
concentrations of PMA. Cross-toxicity assays showed a decrease in cell viability when 
transfecting A549 cells with PPRHs against PD1, whereas this effect was not observed 
in THP-1 transfected with PPRHS against PDL-1. Co-culture experiment showed that the 
combination of PPRHs against PD1 and PDL-1 produced an enhancement of the 
antitumor effect, compared to their individual effects separately. Our results support the 
usage of PPRHs for the silencing PD1/PDL-1 pathway in lung cancer. 
 





El càncer de pulmó es un dels càncers amb pitjor pronòstic, però a l’hora es un dels 
que millor respon a la immunoteràpia. Una de les estratègies d’immunoteràpia contra 
aquest càncer és el silenciament de la via PD1/PDL-1, la qual es troba sobreexpressada 
en els càncers de pulmó. Recentment, s’ha descobert una nova tecnologia per silenciar 
gens, els PPRHs, els quals han estat prèviament assajats per inhibir  la via de PD1/PDl-1 
en altres tipus de càncer. En aquest projecte, l’objectiu principal ha sigut validar la 
tecnologia dels PPRHs com a possible tractament de l’adenocarcinoma pulmonar, 
mitjançant el silenciament de la via PD1/PDL-1. Les cèl.lules THP-1 van ser 
diferenciades a macròfags utilitzant tres concentracions diferents de PMA. Es van 
dissenyar PPRHs contra PD1 i PDL-1 i es van transfectar creuadament  a les cèl.lules 
A549 i THP-1. També es va realitzar un co-cultiu amb cèl.lules THP-1 diferenciades i 
A549 en presència dels PPRHs contra PD1 i/o PDL-1. La viabilitat cel·lular es va 
determinar mitjançant assaigs de MTT. La diferenciació de THP-1 a macròfags no va 
mostrar diferencies significatives a les diferents concentracions de PMA. En els assaigs 
de toxicitat creuada es va observar que la viabilitat de les cèl.lules A549 disminuïa amb 
anti-PD1. A l’experiment de co-cultiu es va observar com la combinació de PPRHs contra 
PD1 i PDL-1 produïa una potenciació de l’efecte antitumoral. Finalment vam poder 
concloure que els PPRHs contra PD1 i PDL-1 podrien ser una estratègia valida contra el 
càncer de pulmó. 
 





A549: Lung Adenocarcinoma cell line  
aODNs: Antisense Oligonucleotides 
APC: Antigen Presenting Cell 
CNT: Control 
CTLA4: T-Lymphocyte-Associated protein 4 
DMSO: Dimethyl Sulfoxide 
DNA: Deoxyribonucleic Acid 
DOTAP: N-[1-(2,3-dioleoyloxy) propyl]-N,N,N-trimethylammonium methylsufate 
E1: Exon 1 
EDTA: Ethylenediaminetetraacetic acid 
FDA: Food and Drug Administration 
I1/2/4: Intron 1/2/4 
IASLC: International Association for the Study of Lung Cancer 
IFN-α: Interferon α 
IL-2: Interleukin 2 
MHC I/II: Major Histocompatibility Complex I/II 
miRNA: MicroRNA 
MTT: 3- (4,5-Dimethylthiazol-2-yl) -2,5-Diphenyl-tetrazolium Bromide 
NCHS: National Center for Health Statistics  
NCI: National Cancer Institute 
NSCLC: Non-Small Cell Lung Cancer 
PBS: Phosphate Buffered Saline 
PD1: Programmed cell Death 1 
PDL-1/2: Programmed cell Death Ligand 1/2 
PMA: Phorbol 12-Myristate 13-Acetate 
PPRH: Polypurine Reverse Hoogsteen 
PR: Promotor 
RNA: Ribonucleic Acid 
SCLC: Small Cell Lung Carcinoma 
siRNA: Small interference RNA 
TCR: T-Cell Receptor 
TFOs: Triplex Forming Oligonucleotides 
 6 
THP-1: Human Monocyte Leukemia cell line 




DISCUSSION JUSTIFYING WORK INTEGRATION OF THE AREAS 
INCLUDED IN THIS PROJECT: 
 
In the present project, various areas of the studies of Pharmacy have been 
integrated. First of all, it was necessary to have knowledge of the field of Physiology and 
Physiopathology, because in this project we studied a disease, lung cancer. Secondly, 
Pharmacology knowledge has been integrated, since in this case we were looking for 
therapeutic targets to treat pulmonary adenocarcinoma. The treatment studied has been 
immunotherapy, so it has also been necessary to appeal to Immunology area to develop 
this research. Lastly, the fields of Molecular Biology and Biochemistry were involved, 
especially in the practical phase of the project, since this knowledge has been necessary 






1.1 Cancer disease: 
 
The term cancer involves a collection of more than 200 related diseases that can 
start almost anywhere in the human body. These diseases are induced by a group of 
cells that have experienced one or more mutations. All these cells have two main 
aspects in common: an uncontrollable proliferation and the ability to spread into 
surrounding tissues (1). 
 
In the last decades, cancer has become a worldwide major health issue. 
According to the National Center for Health Statistics (NCHS) 1762 450 new cancer 
cases and 606 880 cancer deaths were expected in 2019 (2).  
 
Of all types of cancer, the one that leads to the highest number of deaths is lung 
cancer, which represents more than 20% of total cancer deaths. This is the reason to 
focus our study on this type of cancer (2).  
 
1.2 Lung cancer: 
 
Bronchogenic carcinoma, also known as lung cancer, comprehends all types of 
malignant tumors of epithelial lines, which originate from the lining or glandular 




As claimed by the World Health Organization (WHO) and the International 
Association for the Study of Lung Cancer (IASLC), two major types of lung 
cancer can be distinguished: Small Cell Lung Carcinoma (SCLC) and Non-Small 
Cell Lung Carcinoma (NSCLC). As it can be seen, the name given to each of the 
types refers to the size of the cells that conform the tumor (4). 
 
SCLC represents 20% of all lung cancers. This type is the most aggressive 
one and also the one with worst prognostic, attributable to its greater tendency to 
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spread to other organs. SCLC tumors are composed by small cells with scarce 
cytoplasm presenting neurosecretion granules on it, they are usually oval, round 
or fusiform. Two main characteristics of this kind of tumors are its high mitotic 
rate and the abundant necrosis (4).  
 
The remaining 80% of lung tumors are classified as NSCLC. According to 
the NCHS, NSCLC usually have a better prognostic and a lower death rate, due 
to a greater response to treatments and slower cell division. Cells that conform 
this type of lung cancer are bigger than in SCLC, with a greater amount of 
cytoplasm, but without neurosecretion granules on it, and also visible nucleoli 
(2,4). 
 
The Non-Small Cell Lung Cancer type can be divided in 3 subcategories: 
Squamous Cell Carcinoma, Adenocarcinoma and Large Cell Carcinoma, being 
the Adenocarcinoma the most common one, approximately 40% of cases, 
followed by Squamous Cell Carcinoma and finally Large Cell Carcinoma (5). 
  
1.2.2 Symptomatology and diagnosis:  
 
The main problem of lung cancer is that it does not present a clear 
symptomatology until it reaches advanced stages of the disease, which explains 
why, nowadays, there is no early diagnosis (6). 
 
Depending on the location of the tumor and the stage of the disease, 
different signs and symptoms can be observed. The most frequent ones are cough, 
usually with expectoration, hemoptysis, dyspnea and thoracic pain. In advanced 
stages of the disease more symptoms can be noticed, such as bone pain, tiredness, 
anorexia and others related to possible metastases (6). 
 
Lung cancer diagnosis can be performed using different types of tests, some 
of them more invasive than others. The non-invasive ones are chest X-ray, sputum 
cytology, spirometry, computed tomography and positron emission tomography, 
this last being the most sensitive. Other available tests, such as bronchoscopy and 
fine needle puncture, are considered as invasive techniques (5,6). 
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1.2.3 Prognostic:   
 
As stated by the Spanish Association Against Cancer, lung cancer survival 
after 5 years is less than 15%, becoming one of the cancers with worst prognostic, 
along with liver, esophagus and pancreas. If patients diagnosed with advanced 
stage do not receive treatment, their life expectancy does not exceed 6 months. 
However, it has been observed that diagnosed patients in asymptomatic stages 
showed an increase up to 70% in the survival rate after 5 years (7). 
 
1.2.4 Treatments:  
 
The treatment to choose for lung cancer depends on different factors such 
as the anatomopathological classification, SCLC or NSCLC, in addition to the 
stage of the disease, either initial and localized or advanced with metastasis. 
 
In the case of SCLC, if the patients are diagnosed with a limited disease, the 
treatment will probably be a combination of chemotherapy and radiotherapy. 
However, when the disease is widespread, palliative chemotherapy is given, since 
its rarely curable (8).  
 
On the other hand, when it comes to NSCLC, if the disease is found in early 
stages (localized disease) the treatment of choice will be surgery. However, only 
24% of cases are diagnosed in early stages, which implies that most of patients 
will have locally advanced or disseminated disease, and in these two scenarios, 
chemotherapy and/or radiotherapy will be the chosen treatments, whereas surgery 
will be the second option (5). 
 
Although surgery, chemotherapy and radiotherapy are conventional 
treatments, there are many other treatments that can be used against lung cancer, 




In the last decade, immunotherapy has been gaining ground over other 
treatments, due to its surprising and durable results, in addition to its low toxicity 




The use of a therapy that is capable of boosting the patient's immune system, 
to help them fight a disease such as cancer, with fewer off-target effects, 
represented a complete revolution in oncology and research on this field has not 
stopped growing (9,10). 
 
The history of this therapy starts back in 1980, when the use of cytokines to 
treat some types of cancer locally and systematically was found out, although the 
great revolution took place in 2011 with the discovery of checkpoint inhibitors 
(11). 
 
The idea of immunotherapy relies on the insight that the immune system, in 
a process named immune surveillance, can eliminate cancerous cells during its 
initial transformation. During oncogenesis, tumors create neo-antigens, which 
should turn these cells into a target for the immune system. But the reality is that 
neoplastic cells are able to escape from the immune system, due to the different 
resistance systems they create, such as induction of tolerance, local immune 
evasion and systemic disruption of T cell signaling (10). 
 
1.3.1 Types of immunotherapy:  
 
There are many types of cancer, and accordingly different types of 
immunotherapy, which include various approaches, from stimulating effector 
mechanisms to counteracting suppressor and inhibitory mechanisms (9,10). The 





Strategy Type Principal Mechanism 
Cytokines IL-2 Stimulating host’s IS. 
IFN-a Stimulating host’s IS. 
Cell based 
therapies 
Vaccines Stimulating host’s IS. 
Adoptive cellular therapy High avidity in effector T 
cells and omits the task of 





CTLA-4 Unleash pre-existing 
anticancer T cell responses 
and possibly triggers new 
ones. 
Anti PD1/ PDL-1 
antibodies 
Enhances T cell response 





responses and immunity. 
Table 1: Summary of existing types of immunotherapy and examples (10). 
 
1.3.2 Immunotherapy and Lung Cancer: 
 
As previously described, lung cancer is one of the most aggressive type of 
tumors, with the worst prognosis and responsible for the greatest number of deaths 
in the world, but surprisingly it is also one of the types of cancer that best responds 
to immunotherapy treatment (12). 
 
It is worth mentioning that lungs are the way of entry for many external 
agents, and thus they are rich in various types of immune cells. Furthermore, 
pulmonary oncogenesis is often caused by inflammatory alterations due to 
immune defects such as T cell alterations, B-Lymphocyte defects, natural killer 




The use of immunotherapy is being especially limited to patients diagnosed 
with advanced stages of NSCLC, although more recently, testing has also begun 
in SCLC cases (8). Even so, in this work we will focus on NSCLC.  
 
For the reasons mentioned above, considerable time is currently being spent 
on researching new treatments for lung cancer based on the exploitation of the 
patient's immune system. There are currently two different groups of 
immunotherapies against this type of cancer: passive and active immunotherapy 
(12). 
 
Passive immunotherapy can be divided into two types, dendritic cell based 
and adoptive transfer of ex-vivo-activated T-cells. The antitumor activity of both 
is based on the incorporation of components of the immune system, either from 
donors or performed in the laboratory, to the patient (12). 
 
On the other hand, active immunotherapy can be divided into two types, 
antigen-dependent immunotherapy, which it is based on the use of vaccines, and 
antigen-independent immunotherapy, which works by blocking immune 
checkpoints (12). 
 
It should be noted that presently, the type of immunotherapy with best 
results against lung cancer is the active antigen independent (Checkpoint 
Blockade) (14). 
 
1.3.3 Checkpoint Blockade: 
 
The most important effector cells against tumors are CD8+ cytotoxic and 
CD4+ helper T cells, since both are responsible for mediating humoral and cell-
mediated responses. The activation of T lymphocytes begins when Antigen 
Presenting Cells (APC), through their Major Histocompatibility Complexes 
(MHC-I / MHC-II) present antigens to T lymphocytes, which recognize them by 
their receptor (TCR). Complete activation, differentiation and proliferation occurs 
thanks to other costimulatory factors such as CD28 (15,16). 
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The immune system is self-regulated through co-stimulatory and co-
inhibitory molecules, with the aim of maintaining homeostasis. Both strategies 
are equally important, since the first one allows to obtain an efficient response 
against possible pathogens, whereas the second one controls that this response is 
not excessive (16). 
 
T lymphocytes, therefore, also have their own regulatory molecules, the 
most prominent being the co-inhibitory molecules of the immune checkpoint, in 
charge of regulating both the duration and the amplitude of the response of T cells.  
These co-inhibitory molecules comprehend T-lymphocyte-associated protein 4 
(CTLA4), programmed cell death 1 (PD1), and programmed death ligands (PDL-
1 / PDL-2) (11,17).  
 
 
Figure 1: Cancer Immunity (Modified Image) (11). 
 
As mentioned above, cancer cells are able to evade the immune system, and, 
in the case of NSCLC, it has been observed that resistance mechanisms are due to 
inhibitory molecules located in the tumor microenvironment. Among all 
inhibitory molecules, two types should be highlighted: the immune inhibitory 
ligand-receptor interaction, which are related to the CTLA4 and PD1, and the 
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membrane inhibitory ligands (also known as checkpoint ligands) which are PDL-




The inhibitory molecule CTLA4 is found on the surface of 
activated T lymphocytes and competes with CD28 (costimulatory 
molecule) to bind to its ligands. CTLA4 is in charge of regulating the 
amplitude of the T cell response (11,16). 
 
In patients with NSCLC, the expression of CTLA4 is increased, 
and thus the response of T lymphocytes will be directly reduced, since 
it can bind more easily to ligands, causing a decrease in the activation 
of T cells, promoting a downregulation of antitumor immune response 
(14,16). 
 
For this reason, antibodies as possible inhibitors of this molecule 
have been studied, in order to boost the anti-tumor response of T cells. 
It should be noted that, although the response of these antibodies has 
been good in combined therapy, treatments against PD1 and PDL-1 have 




The PD1 receptor can be found on the surface of various cells of 
the immune system, including T or B lymphocytes and Natural Killer. 
Right after antigen recognition, T cells express PD1 on their surfaces. 
This molecule has two ligands PDL-1 and PDL-2, which can be found 
in different cell lines. PDL-1 expression can be induced both by the 
presence of inflammatory cytokines and by oncogenes, which explains 
PDL-1 overexpression in various tumors, especially NSCLC (15,16). 
 
The binding of PD1-PDL-1 causes a downregulation of the 
immune system, since it decreases the production of inflammatory 
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cytokines and cytotoxic activity, and will end up causing the death of 
T lymphocytes, and thus promoting an escape route for tumor cells 
(16,18). 
 
In various studies, it has been observed that the blockade of this 
pathway leads to an increase in effector T cells and in the cytotoxic 
activity of tumor-specific T cells, enhancing the activity of tumor 
infiltrating T cells and T regulatory cells, boosting the immune system 
(15). 
 
For this reason, in recent years, studies have focused on the 
search for monoclonal antibodies capable of inhibiting the binding of 
PD1/PDL-1, either by blocking PD1 receptors or its PDL-1 ligand. In 
2017, two anti PD1 antibodies (Nivolumab and Pembrolizumab) and 3 
anti PDL-1 (Atezolizumab, Avelumab and Durvalumab) were 
approved by the Food and Drugs Administration (FDA) (14,18). 
 
The pharmacological profile of these monoclonal antibodies is 
highly favored, due to their low side effects, which are usually mild 
and revert when treatment is suspended, in addition to their advantages 
due to their good antitumor activity and their long-lasting responses 
(15).  
 
1.4 PPRHs technology:  
 
There are certain diseases whose treatment are based on gene silencing, 
decreasing expression of certain genes. The most used molecules to produce gene 
silencing are the following: small-interference RNA (siRNA), microRNA (miRNA), 
antisense oligonucleotides (aODNs) and Triplex Forming Oligonucleotides (TFOs) 
(19). 
 
In recent years, a new technology called Polypurine Reverse Hoogsteen 
Hairpins (PPRHs) has emerged, which does not have some of the drawbacks of the 
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above-mentioned molecules, such as low stability and the response of the immune 
system (19). 
 
PPRHs are DNA hairpins consisting of two antiparallel polypurine domains, 
without nucleotide modifications. These strands are linked by a pentathyamidine 
loop, which allows the formation of intramolecular reverse Hoogsteen bonds. 
Hairpins can be linked by Watson and Crick bounds to the DNA, provided that it has 
polypirimidine targets, which are usually found in promoters and introns. Targets for 
PPRHs can be found in both of the DNA strands, meaning that PPRHs can be directed 
against either the coding or the template strands. When PPRHs bind to the DNA, they 
cause a strand displacement, inhibiting transcription (19–21). 
 
 
Figure 2: Template and coding PPRHs (19).  
 
 The effectiveness of PPRHs in cancer immunotherapy has been tested in different 
cell lines, targeting different genes related to the immune system. The use of this 
technology against the PD1/PDL-1 tandem has been previously tested in prostate, cervix, 
breast and melanoma cancer cells, in which a decrease in mRNA and protein levels of 
both genes have been observed. In addition, in co-culture experiments with PDL-1-
transfected tumor cells, together with PD1-transfected macrophages, a reduction of at 
least 65% in the viability of the tumor cells could be observed (20,21). 
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In the present work, our aim is to evaluate the silencing PD1 and PDL-1 by means 
of the PPRH technology in lung adenocarcinoma cells. 
 
2. OBJECTIVES:  
 
During the present research project, the main objective has been to validate 
Polypurine Reverse Hoogsteen strategy as a possible treatment of pulmonary 
adenocarcinoma, by silencing the PD1/PDL-1 pathway.  
 
3. MATERIALS AND METHODS: 
 
3.1 Cell culture 
 
 Adenocarcinoma A549 cells, representative of the most common type of tumor 
within non-Small Cell Lung Cancer, and THP-1 cells (Human Monocyte Leukemia) 
commonly used as a model of macrophages were the cell lines used in this work.  
 
Culture of both cell lines was performed using Ham’s F-12 medium supplemented 
with 10% fetal bovine serum (both from Gibco, Barcelona, Spain). Cell culture conditions 
were as follows: temperature of 37ºC in a humidified 5% CO2 controlled atmosphere. 
A549 cells grow attached, so it was necessary to perform trypsinizations, for which it was 
used 0.05% trypsin in PBS 1X (154 mM NaCl, 3.88 mM H2NaPO4 and 6.1 mM HNaPO4 
pH 7.4) (Sigma-Aldrich, Madrid, Spain). THP-1 cells grow in suspension, so no 
trypsinization was needed. 
 
Both A549 and THP-1 were maintained frozen in liquid N2 tanks at approximately 
-150° C, so it was necessary to thaw them first. Once thawed, they were centrifuged in 
order to eliminate the freezing medium (with a high content of dimethyl sulfoxide 
(DMSO), toxic for the cells) and were subsequently resuspended with Ham’s F-12 
medium supplemented with 10% fetal bovine serum. 
 
A549 and THP-1 cells were plated in cell culture dishes and incubated for 24 hours 
under optimal growth conditions (37 ºC, 5% CO2 controlled humified atmosphere) to 
ensure their viability, before any experimental procedure. 
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3.2  THP-1 Differentiation 
 
Differentiation of THP-1 cells to macrophages was performed in the presence of 3 
different concentrations (1, 2 and 3 ng/ml) of phorbol 12-myristate 13-acetate (PMA) 
(Sigma-Aldrich, Madrid, Spain) dissolved in DMSO. After 72 hours of incubation under 
optimal conditions (37 ºC, 5% CO2 controlled humified atmosphere), adhesion of the cells 
to the dishes was visually evaluated, as a control parameter for differentiation. 
 
3.3 Design of PPRHs 
 
The PPRHs used in the present co-culture experiment were designed using the 
Triplex Oligonucleotide Target Sequence Search Software 
(http://utw10685.utweb.utexas.edu/tfo/, Austin, Texas, USA), a program capable of 
finding polypurine sequences in the genes of interest. 
 
The sequences of the PPRHs against PD1 and PDL-1 and their abbreviations are 
shown below: 
 
PPRHS AGAINST PD1 
Name Sequence (5'-3') Position 
HPPD1-PR 
GAGCAGAGACACAGAGGAGGAAGGG     T     T 
Promoter                  T 
GAGCAGAGACACAGAGGAGGAAGGG     T     T 
HPPD1-E1 
AGGCGGAGGTGAGCGGAAGGGAAA      T     T 
Exon 1                                                                                                          T 
AGGCGGAGGTGAGCGGAAGGGAAA      T     T 
HPPD1-I4 
GAGGAGAAAGGGAGAGGGAG     T     T 
Intron 4                                                                                      T 
GAGGAGAAAGGGAGAGGGAG     T     T 






PPRHS AGAINST PDL-1 
Name Sequence (5'-3') Position 
HPPDL-1-I1 
GGGATGGAGAGAGGAGAAGGGAAAGGGAA     T    T 
Intron 1 T 
GGGATGGAGAGAGGAGAAGGGAAAGGGAA    T    T 
HPPDL-1-I2 
AGTGGTGAAGGGAGGAGGGACA    T     T 
Intron 2 T 
AGTGGTGAAGGGAGGAGGGACA     T     T 
Table 3: Sequences of the PPRHs against PDL-1. 
 
The synthesis of the PPRHs was carried out by Sigma Aldrich (Haverhill, United 
Kingdom). PPRHs were resuspended in TE buffer (1mM Ethylenediaminetetraacetic acid 
(EDTA) and 10mM Tris, pH 8) and stored at -20ºC until their use. 
 
3.4 Transfection of PPRHs 
 
Transfection of PPRHs was carried out using DOTAP (N-[1-(2,3-dioleoyloxy) 
propyl]-N,N,N-trimethylammonium methylsufate) (Biontex, München, Germany), a 
delivery system capable of transferring DNA to cultured cells. This system was 
previously used in other studies, in which it was observed that the optimal ratio between 
DOTAP and PPRH was 1:100 (22). 
 
The mixture used for the transfection was 100 nM of PPRH with 10 µM of DOTAP 
in a 200 µl final volume. The final 200 µl solution was incubated at room temperature for 
20 minutes. Subsequent to said incubation, the 200 µl of solution were added into the 
appropriate well, obtaining a final volume of 1 ml in each. 
 
3.5 Cross-citotoxicity experiments 
 
Cross-citotoxicity experiments were carried out by plating 6 well-dishes with THP-
1 and A549 cells separately, and later transfected with the corresponding PPRHs, THP-1 
cells were transfected with PPRHs against PDL-1 (I1 and I2) whereas A549 cells were 
transfected with PPRHs against PD1 (I4, E1 and PR). Cells were incubated for 4 days, 
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under optimal conditions (37 ºC, 5% CO2 controlled humified atmosphere) and on the 
fourth day, cell viability was determined by MTT assays. 
 
3.6 Co-culture experiments 
 
First, THP-1 were plated in 6-well dishes and transfected with PPRHs against PD1 
(I4, E1 and PR). After 24 hours of transfection, the process of differentiation of THP-1 
into macrophages began, by adding 2 ng/ml of PMA to the culture medium. 
 
After incubating the dishes for 72 hours, cells were already differentiated into 
macrophages. Then the culture medium with the remaining PMA was aspirated, and A549 
cells were plated together with the macrophages and incubated for 6 hours, to ensure their 
correct adhesion to the plate. After this time period, tumor cells were transfected with 
PPRHs against PDL-1 (I1 and I2). 
 
Co-cultures were incubated for 4 days under optimal conditions for growth. Cell 
viability was assessed after those 4 days by MTT assays.  
 
3.7 MTT assays 
 
MTT assays are commonly used to measure cell viability, by the determination of 
the mitochondrial activity. After four days of incubation of the cells in the different 
experimental conditions, the assay was started by adding the following reagents to each 
well: 500 μg/ml of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl-tetrazolium bromide 
(MTT) and 100 μM of sodium succinate (Sigma Aldrich, Madrid, Spain). This mixture 
was incubated at 37ºC for two and a half hours, in order to ensure optimal reaction 
conditions. 
 
Subsequently, after aspirating the culture medium, lysis solution (24V isopropanol 
and 1V of HCl 1M) was added (Sigma Aldrich, Madrid, Spain). Cell viability was 
measured with a Modulus microplate luminometer (Turner Biosystem Promega, Madrid, 
Spain) at a wavelength of 570 nm. Results were expressed as the percentage of cell 
survival relative to non-transfected control cells. 
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Below these lines, a complete scheme of the co-culture experiment is shown: 
 
 
Figure 3: Coculture experiment (21). 
 
4. RESULTS AND DISCUSSION:  
 
4.1 Effect of PMA on THP1 cells 
 
In order to check whether the concentration of PMA could affect the differentiation 
of THP1 to macrophages, we decided to test three different concentrations of the reagent: 
1, 2 and 3 ng/ml. 
 
First, we proceeded to plate a 6-well-dish with 10,000 THP-1 cells per well, so it 
was necessary to count the cells first, with the help of the Chamber of Neubauer. After 
performing the calculations, we were able to obtain the volume of cell suspension that we 
had to add into each well to obtain 10,000 cells, this was 34.2 µl, so we pipetted this 
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volume in a final volume of 1 ml of Ham’s F-12 medium supplemented with 10% fetal 
bovine serum.  
 
Secondly, to proceed with the differentiation it was necessary to have a 1ng/µl 
phorbol 12-myristate 13-acetate (PMA) solution. The stock solution was 100 ng/µl, so it 
was necessary to make two 1:10 dilutions, using dimethyl sulfoxide (DMSO) as a diluent, 
to obtain the desired solution. 
 
Finally, the PMA solution (1 ng/µl) was added to each well. As mentioned above, 
3 different concentrations were tested corresponding to 1, 2 and 3 µl of the PMA solution. 
The assay was performed in duplicate, as shown in the following scheme: 
 
 
Figure 4: Scheme of PMA experiment. 
 
The 6 well-dish was incubated for 3 days under optimal conditions for 
differentiation (37 ºC, 5% CO2 controlled humified atmosphere). On the third day, we 
visually checked with a microscope whether the monocytes had differentiated, observing 
if they had adhered to the dish, and we saw that there were no significant differences 
among the different concentrations of PMA. 
 
These results are in agreement with a previous study in which the differentiation of 
THP1 to macrophages was carried out with PMA. It was observed, after testing the three 
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concentrations mentioned above and determining differentiation markers, that there were 
no significant differences between 1 and 3 ng / ml PMA (23). 
 
4.2 Assessment of the cross-toxicity of PPRHs 
 




Figure 5: Scheme of cross-toxicity experiment. 
 
As it can be seen in Figure 5, 6 well-dishes were used, in which the following 
conditions were tested: 
 
o A549 and THP-1 control cells (non-transfected). 
o 60,000 A549 cells transfected with anti PD1 (I4, E1 and PR). 
o 80,000 A549 cells transfected with anti PD1 (I4, E1 and PR). 
o 10,000 THP-1 cells transfected with anti PDL-1 (I1 and I2). 
 
First, we proceeded to plate A549 and THP1 cells, a process for which it was 
necessary to count the cells using the Neubauer Chamber, following the order established 
during the experimental design. Two different numbers of A549 cells were used, for 
60,000 it was necessary to pipet 119 µl of the cell suspension, while for 80,000 it was 158 
µl. Finally, for 10,000 THP-1 cells, a volume of 34.3 µl was necessary. For the next step 
it was necessary to have a final volume of 800 µl in each well, so we added Ham’s F-12 
medium supplemented with 10% fetal bovine serum until obtaining the desired volume. 
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Next, we prepared the transfection mixtures for the different PPRHs against PD1 
and PDL-1, by mixing 7,75 µl of DOTAP with 10 µl of the 10 µM solution of the 
corresponding PPRH, and 182,25 µl of serum-free medium, to reach a final volume of 
200 µl. After 20 minutes at room temperature, the transfection mixtures were added to 
the cells. 
 
After 4 days of transfection, we carried out MTT assays in order to determine cell 
viability. The results obtained after transfecting THP-1 with PPRHs against PDL-1 are 
shown in the table below: 
 
THP-1 CELLS 
CONDITION % Viability 
CNT 100,00 
+ PPRH I1 50,18 
+ PPRH I2 175,55 
Table 4: THP-1 cell viability, tested with PPRHs against PDL-1 
 
 
Figure 6: THP-1 cell viability in the presence of PPRHs against PDL-1 
 
As shown in Figure 6, transfection of THP-1 cells with PPRH I1 against PDL-1 
caused a reduction of almost 50% in cell viability, whereas PPRH I2 increased cell 












CNT THP-1 I1 I2
% CELL VIABILITY THP-1 (anti-PDL1)
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Another study had tested the toxicity of PPRHs against PD1, instead of PDL-1 in 
THP-1 cells, in which it was observed that the transfection of PPRHs against PD1 in this 
cell line did not cause significant effects on cell viability (21). 
 
The following table shows the results obtained after performing the MTT assay on 
the A549 transfected with the PPRHs against PD1: 
 
A549 CELLS 
 CONDITION % Viability 
Control CNT 100,00 
60.000 
+ PPRH I4 49,73 
+ PPRH E1 63,14 
+ PPRH PR 58,75 
80.000 
+ PPRH I4 69,02 
+ PPRH E1 85,97 
+ PPRH PR 82,64 
Table 5: A549 Cell viability, tested with PPRHs against PD1 
 
 













CNT A549 I4 E1 PR I4 E1 PR






We also evaluated the cross-toxicity effects of the PPRHs against PD1 in A549 
cells. In this case, all PPRHs decreased cell viability, being I4 the responsible for the most 
pronounced decrease, both with 60,000 and 80,000 cells. 
 
In prostate cancer cells, no cytotoxic effects were observed when transfecting these 
cells with PPRHs against PD1 (21), thus the difference in cell viability could be due to 
an increase of sensitivity of A549 to PPRH transfection. 
 
On the other hand, toxicity of PPRHs against PDL-1 in prostate cancer cells was 
also determined. Both PPRHs against I1 and I2 caused up to a 65% decrease in cell 
viability (21). 
 
The reason to work with two different numbers of cells, 60.000 and 80.000, was to 
see if cell density could affect PPRH toxicity, in accordance with the study referred above 
(21). Bener et al. performed co-culture experiments with 60,000 breast cancer cells (23). 
In our case, we finally decided to use 60,000 A549 cells in the co-culture experiments, 
due to the high rate of cell division for this cell line. 
 
4.3 Evaluation of the effect of PPRHs on cell viability in co-culture experiment: 
 
To evaluate the combined effect of PPRHs on cell viability, we designed a co-




Figure 8: Scheme of the co-culture experiment. 
 
The experiment was carried out in three 6-well-dishes, in which we tested the 
following conditions: 
 
o Coculture of A549 and THP1 without transfection: CNT COCU. 
o THP1 transfected with PPRHs against PD1 and differentiated: CNT MACRO. 
o Transfection of individual PPRHs in co-cultures: I4, E1, PR, I1 and I2. 
o Combination of PPRHs against PD1 and against PDL-1 in co-cultures: I4+I1, 
I4+I2, E1+I1, E1+I2, PR+I1 and PR+I2. 
 
In order to carry out this experiment, first 10.000 THP1 were plated in each well, a 
process for which it was necessary to perform the counting through the Neubauer 
chamber. We pipetted 26.5 µl of cell suspension for 10,000 cells. For the subsequent 
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transfection, a final volume equal to 800 µl was necessary, so we also added 773.5 µl of 
Ham’s F-12 medium supplemented with 10% fetal bovine serum to each well. 
 
Next, we proceeded to prepare 200 µl of transfection mixtures of the PPRHs against 
PD1 (I4, E1, PR), by mixing 182.25 µl of serum-free medium, 7.75 µl of DOTAP and 10 
µl of the 10 µM solution of the corresponding PPRH. After 20 minutes at room 
temperature, the mixtures were added to the corresponding wells. 
 
Twenty-four hours after transfection, we started differentiating THP1 into 
macrophages by adding 2 ng/ml of PMA in each well and incubating for 3 days. On the 
third day, we visually checked that THP1 cells have been correctly differentiated to 
macrophages and aspirated the medium to start the co-culture. 
 
We plated 60,000 A549 cells in all wells except those marked as macrophage 
control. This number of cells corresponded to 59.5 µl of cell suspension, in addition to 
740.5 µl of Ham’s F-12 medium supplemented with 10% fetal bovine serum. Before 
transfection, we incubated the co-culture for 6 hours. 
 
Finally, we prepared the transfection mixtures of the PPRHs against PDL-1 (I1 and 
I2), as previously described. After 20 minutes of incubation at room temperature, the 200 
µl of transfection mixture were added into each well. 
 
Co-cultures were incubated for 4 days. On the fourth day, we carried out the MTT 
analysis. Cell viability was determined taking into account the absorbance of 
macrophages alone, which was subtracted from the total absorbance, in order to obtain 
the value for A549 cells. Cell viability was expressed as the percentage of living 
transfected A549 cells compared to non-transfected A549 cells. The results for the co-







A549 CELL VIABILITY 
CONDITION % Viability 
CNT 100,00 
+ PPRH I4 100,00 
+ PPRH E1 95,84 
+ PPRH PR 81,93 
+ PPRH I1 59,87 
+ PPRH I2 42,32 
Table 6: Cell viability, testing PPRHs individually. 
 
 
Figure 9: % of cell viability compared to the control cells when testing individual PPRH. 
 
As can be seen in the previous figure, PPRHs against PD1 tested individually, did 
not cause a significant decrease in A549 cell viability, while those directed against PDL-
1 affected cell survival up to 60%.  
 
In a similar study, Medina Enríquez et al. reported, as in our experiment, that 
PPRHs directed against PDL-1 (I1 and I2) caused a greater decrease of prostate cancer 














CNT COCU I4 E1 PR I1 I2
% CELL VIABILITY  (INDIVIDUAL PPRH)
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To check if the combination of PPRHs against PD1 and PDL-1 could lead to an 
enhancement in tumor cell death, we transfected both THP1 and A549 cells in the same 
co-culture with all possible combinations. The cell viability results are shown below. 
 
Table 7: Cell viability, testing PPRHs combined. 
 
 
Figure 10: % of cell viability compared to the control cells when testing PPRHs in combination. 
 
The above graph shows the results of cell viability, using all possible combinations 
of PPRHs against PD1/PDL-1. It should be noted that all combinations reduced cell 
viability by at least 55%, with the steepest decrease corresponding to the PR/I2 












CNT COCU I4/I1 E1/I1 PR/I1 I4/I2 E1/I2 PR/I2
% CELL VIABILITY  (PPRH COMBINATION)
A549 CELL VIABILITY 
CONDITION % Viability 
CNT COCU 100,00 
+ PPRH I4/I1 50,06 
+ PPRH E1/I1 47,84 
+ PPRH PR/I1 54,11 
+ PPRH I4/I2 41,61 
+ PPRH E1/I2 44,35 
+ PPRH PR/I2 38,48 
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The combination of PPRHs against PD1 and PDL-1 in co-culture experiments with 
prostate, pancreas, melanoma and breast tumor cells was previously assayed. The most 
effective combinations were PR/I1 in prostate cancer, E1/I1 in melanoma and pancreatic 
cancer and E1/I2 in breast cancer. These results could indicate that cell response to 




o The usage of the PPRHs technology against the PD1 and PDL-1 pathway 
markedly reduces the viability of lung adenocarcinoma cells. 
 
o Transfection of A549 cells with PPRHs against PD1 could represent a new 
approach as anticancer treatment in lung cancer. 
 
o Silencing of both PD1 and PDL-1 by PPRHs enhances tumor cell death. 
 
o PPRHs against PD1 / PDL-1 could be a new research strategy in the field 
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